세계의 알레르기 면역치료 : 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)

The global market for Allergy Immunotherapy was estimated to be worth US$ 1785 million in 2024 and is forecast to a readjusted size of US$ 2805 million by 2031 with a CAGR of 7.0% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Allergy Immunotherapy cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Allergen immunotherapy, also known as desensitization or hypo-sensitization, is a medical treatment for some types of allergies. It is useful for environmental allergies, allergies to insect bites, and asthma. Its benefit for food allergies is unclear and thus not recommended. Immunotherapy involves exposing people to larger and larger amounts of allergen in an attempt to change the immune system's response. The primary therapeutic goals of allergy immunotherapy (AIT) include reducing symptoms, reducing symptomatic medication use, and improving allergyrelated quality of life. The evidence is strong that AIT achieves these goals and can alter the course of the disease, with benefits persisting in many patients for several years after treatment discontinuation.

The global allergy immunotherapy market is primarily driven by the rising prevalence of allergic conditions, such as allergic rhinitis, asthma, and food allergies, which affect hundreds of millions of individuals worldwide. Growing awareness about long-term treatment options and the effectiveness of immunotherapy in providing sustained symptom relief is increasing its adoption. Additionally, advancements in diagnostic techniques, improved formulations such as sublingual tablets, and support from regulatory authorities have facilitated market growth. The increasing demand for personalized medicine and a shift toward disease-modifying therapies are further propelling the market forward.

Despite its therapeutic potential, the allergy immunotherapy market faces several challenges. The long treatment duration-often lasting three to five years-can lead to poor patient compliance and high dropout rates. High upfront costs and limited reimbursement in some regions restrict accessibility for many patients. Moreover, the requirement for specialized healthcare infrastructure and trained professionals, especially for subcutaneous immunotherapy, limits adoption in low-resource settings. Safety concerns, including the risk of systemic allergic reactions, also hinder broader acceptance, particularly among pediatric and elderly populations. These barriers collectively slow market penetration and limit the therapy's full potential.

This report aims to provide a comprehensive presentation of the global market for Allergy Immunotherapy, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Allergy Immunotherapy by region & country, by Type, and by Application.

The Allergy Immunotherapy market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Allergy Immunotherapy.

Market Segmentation

By Company

• ALK-Abello
• Stallergenes Greer
• Merck
• Allergy Therapeutics
• HAL
• Holister Stier
• Leti
• WOLW Pharma

Segment by Type

• Subcutaneous Immunotherapy
• Sublingual Immunotherapy

Segment by Application

• Allergic Rhinitis
• Allergic Asthma
• Others

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Allergy Immunotherapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Allergy Immunotherapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Allergy Immunotherapy in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Allergy Immunotherapy Product Introduction
• 1.2 Global Allergy Immunotherapy Market Size Forecast
  • 1.2.1 Global Allergy Immunotherapy Sales Value (2020-2031)
  • 1.2.2 Global Allergy Immunotherapy Sales Volume (2020-2031)
  • 1.2.3 Global Allergy Immunotherapy Sales Price (2020-2031)
• 1.3 Allergy Immunotherapy Market Trends & Drivers
  • 1.3.1 Allergy Immunotherapy Industry Trends
  • 1.3.2 Allergy Immunotherapy Market Drivers & Opportunity
  • 1.3.3 Allergy Immunotherapy Market Challenges
  • 1.3.4 Allergy Immunotherapy Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Allergy Immunotherapy Players Revenue Ranking (2024)
• 2.2 Global Allergy Immunotherapy Revenue by Company (2020-2025)
• 2.3 Global Allergy Immunotherapy Players Sales Volume Ranking (2024)
• 2.4 Global Allergy Immunotherapy Sales Volume by Company Players (2020-2025)
• 2.5 Global Allergy Immunotherapy Average Price by Company (2020-2025)
• 2.6 Key Manufacturers Allergy Immunotherapy Manufacturing Base and Headquarters
• 2.7 Key Manufacturers Allergy Immunotherapy Product Offered
• 2.8 Key Manufacturers Time to Begin Mass Production of Allergy Immunotherapy
• 2.9 Allergy Immunotherapy Market Competitive Analysis
  • 2.9.1 Allergy Immunotherapy Market Concentration Rate (2020-2025)
  • 2.9.2 Global 5 and 10 Largest Manufacturers by Allergy Immunotherapy Revenue in 2024
  • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Allergy Immunotherapy as of 2024)
• 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Subcutaneous Immunotherapy
  • 3.1.2 Sublingual Immunotherapy
• 3.2 Global Allergy Immunotherapy Sales Value by Type
  • 3.2.1 Global Allergy Immunotherapy Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Allergy Immunotherapy Sales Value, by Type (2020-2031)
  • 3.2.3 Global Allergy Immunotherapy Sales Value, by Type (%) (2020-2031)
• 3.3 Global Allergy Immunotherapy Sales Volume by Type
  • 3.3.1 Global Allergy Immunotherapy Sales Volume by Type (2020 VS 2024 VS 2031)
  • 3.3.2 Global Allergy Immunotherapy Sales Volume, by Type (2020-2031)
  • 3.3.3 Global Allergy Immunotherapy Sales Volume, by Type (%) (2020-2031)
• 3.4 Global Allergy Immunotherapy Average Price by Type (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Allergic Rhinitis
  • 4.1.2 Allergic Asthma
  • 4.1.3 Others
• 4.2 Global Allergy Immunotherapy Sales Value by Application
  • 4.2.1 Global Allergy Immunotherapy Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Allergy Immunotherapy Sales Value, by Application (2020-2031)
  • 4.2.3 Global Allergy Immunotherapy Sales Value, by Application (%) (2020-2031)
• 4.3 Global Allergy Immunotherapy Sales Volume by Application
  • 4.3.1 Global Allergy Immunotherapy Sales Volume by Application (2020 VS 2024 VS 2031)
  • 4.3.2 Global Allergy Immunotherapy Sales Volume, by Application (2020-2031)
  • 4.3.3 Global Allergy Immunotherapy Sales Volume, by Application (%) (2020-2031)
• 4.4 Global Allergy Immunotherapy Average Price by Application (2020-2031)

5 Segmentation by Region

• 5.1 Global Allergy Immunotherapy Sales Value by Region
  • 5.1.1 Global Allergy Immunotherapy Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Allergy Immunotherapy Sales Value by Region (2020-2025)
  • 5.1.3 Global Allergy Immunotherapy Sales Value by Region (2026-2031)
  • 5.1.4 Global Allergy Immunotherapy Sales Value by Region (%), (2020-2031)
• 5.2 Global Allergy Immunotherapy Sales Volume by Region
  • 5.2.1 Global Allergy Immunotherapy Sales Volume by Region: 2020 VS 2024 VS 2031
  • 5.2.2 Global Allergy Immunotherapy Sales Volume by Region (2020-2025)
  • 5.2.3 Global Allergy Immunotherapy Sales Volume by Region (2026-2031)
  • 5.2.4 Global Allergy Immunotherapy Sales Volume by Region (%), (2020-2031)
• 5.3 Global Allergy Immunotherapy Average Price by Region (2020-2031)
• 5.4 North America
  • 5.4.1 North America Allergy Immunotherapy Sales Value, 2020-2031
  • 5.4.2 North America Allergy Immunotherapy Sales Value by Country (%), 2024 VS 2031
• 5.5 Europe
  • 5.5.1 Europe Allergy Immunotherapy Sales Value, 2020-2031
  • 5.5.2 Europe Allergy Immunotherapy Sales Value by Country (%), 2024 VS 2031
• 5.6 Asia Pacific
  • 5.6.1 Asia Pacific Allergy Immunotherapy Sales Value, 2020-2031
  • 5.6.2 Asia Pacific Allergy Immunotherapy Sales Value by Region (%), 2024 VS 2031
• 5.7 South America
  • 5.7.1 South America Allergy Immunotherapy Sales Value, 2020-2031
  • 5.7.2 South America Allergy Immunotherapy Sales Value by Country (%), 2024 VS 2031
• 5.8 Middle East & Africa
  • 5.8.1 Middle East & Africa Allergy Immunotherapy Sales Value, 2020-2031
  • 5.8.2 Middle East & Africa Allergy Immunotherapy Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Allergy Immunotherapy Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Allergy Immunotherapy Sales Value and Sales Volume
  • 6.2.1 Key Countries/Regions Allergy Immunotherapy Sales Value, 2020-2031
  • 6.2.2 Key Countries/Regions Allergy Immunotherapy Sales Volume, 2020-2031
• 6.3 United States
  • 6.3.1 United States Allergy Immunotherapy Sales Value, 2020-2031
  • 6.3.2 United States Allergy Immunotherapy Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Allergy Immunotherapy Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Allergy Immunotherapy Sales Value, 2020-2031
  • 6.4.2 Europe Allergy Immunotherapy Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Allergy Immunotherapy Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Allergy Immunotherapy Sales Value, 2020-2031
  • 6.5.2 China Allergy Immunotherapy Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Allergy Immunotherapy Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Allergy Immunotherapy Sales Value, 2020-2031
  • 6.6.2 Japan Allergy Immunotherapy Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Allergy Immunotherapy Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Allergy Immunotherapy Sales Value, 2020-2031
  • 6.7.2 South Korea Allergy Immunotherapy Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Allergy Immunotherapy Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Allergy Immunotherapy Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Allergy Immunotherapy Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Allergy Immunotherapy Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Allergy Immunotherapy Sales Value, 2020-2031
  • 6.9.2 India Allergy Immunotherapy Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Allergy Immunotherapy Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 ALK-Abello
  • 7.1.1 ALK-Abello Company Information
  • 7.1.2 ALK-Abello Introduction and Business Overview
  • 7.1.3 ALK-Abello Allergy Immunotherapy Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.1.4 ALK-Abello Allergy Immunotherapy Product Offerings
  • 7.1.5 ALK-Abello Recent Development
• 7.2 Stallergenes Greer
  • 7.2.1 Stallergenes Greer Company Information
  • 7.2.2 Stallergenes Greer Introduction and Business Overview
  • 7.2.3 Stallergenes Greer Allergy Immunotherapy Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.2.4 Stallergenes Greer Allergy Immunotherapy Product Offerings
  • 7.2.5 Stallergenes Greer Recent Development
• 7.3 Merck
  • 7.3.1 Merck Company Information
  • 7.3.2 Merck Introduction and Business Overview
  • 7.3.3 Merck Allergy Immunotherapy Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.3.4 Merck Allergy Immunotherapy Product Offerings
  • 7.3.5 Merck Recent Development
• 7.4 Allergy Therapeutics
  • 7.4.1 Allergy Therapeutics Company Information
  • 7.4.2 Allergy Therapeutics Introduction and Business Overview
  • 7.4.3 Allergy Therapeutics Allergy Immunotherapy Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.4.4 Allergy Therapeutics Allergy Immunotherapy Product Offerings
  • 7.4.5 Allergy Therapeutics Recent Development
• 7.5 HAL
  • 7.5.1 HAL Company Information
  • 7.5.2 HAL Introduction and Business Overview
  • 7.5.3 HAL Allergy Immunotherapy Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.5.4 HAL Allergy Immunotherapy Product Offerings
  • 7.5.5 HAL Recent Development
• 7.6 Holister Stier
  • 7.6.1 Holister Stier Company Information
  • 7.6.2 Holister Stier Introduction and Business Overview
  • 7.6.3 Holister Stier Allergy Immunotherapy Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.6.4 Holister Stier Allergy Immunotherapy Product Offerings
  • 7.6.5 Holister Stier Recent Development
• 7.7 Leti
  • 7.7.1 Leti Company Information
  • 7.7.2 Leti Introduction and Business Overview
  • 7.7.3 Leti Allergy Immunotherapy Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.7.4 Leti Allergy Immunotherapy Product Offerings
  • 7.7.5 Leti Recent Development
• 7.8 WOLW Pharma
  • 7.8.1 WOLW Pharma Company Information
  • 7.8.2 WOLW Pharma Introduction and Business Overview
  • 7.8.3 WOLW Pharma Allergy Immunotherapy Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.8.4 WOLW Pharma Allergy Immunotherapy Product Offerings
  • 7.8.5 WOLW Pharma Recent Development

8 Industry Chain Analysis

• 8.1 Allergy Immunotherapy Industrial Chain
• 8.2 Allergy Immunotherapy Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Allergy Immunotherapy Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Allergy Immunotherapy Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer